Replies to post #425073 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

It seems to me that a rush to validate Flaskworks, not talking about US production particularly, that would probably be right, and it makes me wonder if they would sell off/partner US rights for DCVax-L first, keeping royalties, license Flaskworks only to that partner, keep Direct for further development, with funds and an option to license Direct by such a partner as well. NWBO becomes a drug development company with a focus on dendritic cells, and completely transforms with LP remaining Chairwoman of the board.

More likely, a complete sale, but given that some people think they would not sell so early, trying to think about possible permutations for a gradual sale to a larger company, getting more and more value out of the dendritic cell platform and taking the development further.

I see many different possible permutations of a deal. But the practicalities of shipping everything to the UK for production seems an odd approach for such a complex, customized product. It's almost like a demonstration of certain aspects of production at this time, in anticipation of a deal. I can agree with that notion. Validation of production technology. Something about that to me seems to suggest a larger plan not yet revealed, and we're all like blind people, feeling the trunk, the legs and the body of the elephant and trying to figure out what it is we are sensing.

[marzan]

sukus, I know you know there is very little manual handlings involved in the flaskworks approach. It means less contamination and consistent reproducibility are ensured. I don't know how they do the compatibility testing. Is it on the same tumor? how do they compare the efficacy, on the same human? for how long?? I think the compatibility testing should involve only the quality and quantity of the dc cells from the flaskwork and the Cognate method. I am very ignorant in this subject. Sorry to ask you.